Veru Reports Third Quarter Fiscal 2022 Financial Results; Pr

11.08.2022 - -Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022- -The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will ...

Related Keywords

Miami , Florida , United States , United Kingdom , Massachusetts , Mitchell Steiner , Samuel Fisch , Sexual Health Division , Ar Prostate Cancer Program , European Medicines Agency Emergency Task , Nasdaq , Company To Host Investor Conference Call , Breast Cancer Program , European Union , Veru Inc , Massachusetts Medical Society , Goodrx Inc , Patients For Emergency Use In European Union , Data Monitoring Committee , Company Form , Exchange Commission , Corporate Communications , Healthcare Products Regulatory Agency , European Medicines Agency , Emergency Task Force Initiated Review , Sabizabulin Treatment , Emergency Use , New England Journal , Medicine Evidence Published Phase , Trial Results Demonstrating , High Risk Hospitalized , Company Prepares , Emergency Authorizations Are , Host Investor Conference Call Today , Acute Respiratory Distress , Quarter Financial Summary , Date Financial Summary , Chief Executive Officer , Emergency Use Authorization , Emergency Task , Pipeline Highlights , Disease Franchise , Positive Phase , Hospitalized Moderate , High Risk , Independent Data , Monitoring Committee , Emergency Task Force , Line Treatment , Breast Cancerwith , Combination Therapy , Breast Cancer , Novel Oral Cytoskeleton Disruptor Agent , Metastatic Castration , Antagonist Peptide , Month Subcutaneous Depot Formulation , Androgen Deprivation Therapy , Advanced Prostate Cancer , Benign Prostatic Hyperplasia , Private Securities Litigation Reform Act , Fast Track , Consolidated Statements , Media Contact , Investor Relations ,